BTAI BioXcel Therapeutics Inc
Company Analysis
Latest News
BioXcel Therapeutics fair value jumps 31%, following Phase 3 trial success
Analysts raised the fair value estimate for BioXcel Therapeutics to approximately $18.33 per share. This represents a 31% increase over the previous valuation....
🟢 BioXcel Therapeutics rises 5.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 BioXcel Therapeutics is trading 5.4% up in pre-market after financing deadline extended to August 21, 2026
BioXcel Therapeutics is trading 5.42% up now at $0.83 after an amended credit agreement extended the deadline for securing lender-approved financing or...
🟢 BioXcel Therapeutics trades up 6.39% after credit agreement amendment offers temporary liquidity relief
BioXcel Therapeutics is trading 6.39% up at $0.84 in after-hours, likely reacting to a recent amendment to its credit agreement that eased liquidity covenants...
🔴 BioXcel Therapeutics is trading 10.39% down today after second-quarter results missed EPS and revenue estimates
BioXcel Therapeutics is trading 10.39% down at $0.80 after its August 17, 2026, second-quarter results missed expectations. - EPS was -$0.490 versus -$0.423...
🔴 BioXcel Therapeutics is trading 5.94% down today after second-quarter EPS and revenue missed estimates
BioXcel Therapeutics is trading 5.94% down now at $0.84 after its August 17, 2026, second-quarter results missed analyst expectations. - EPS was -$0.490...
🔴 BioXcel Therapeutics is trading 12.9% down in pre-market after second-quarter results missed expectations
BioXcel Therapeutics is trading 12.9% down at $0.78 after its August 17, 2026, second-quarter results missed expectations. - EPS was -$0.490 versus -$0.423...
🔴 BioXcel Therapeutics is trading 21.01% down today amid severe liquidity concerns
BioXcel Therapeutics is trading 21.01% down at $0.94 after investors reacted to its second-quarter earnings and revenue miss. - EPS came in at -$0.490 versus...
BioXcel's Earnings Miss Deepens the Bleeding — Can a $1 Stock Survive Its Own Cash Burn?
Shares of BioXcel Therapeutics slid 10.1% to $1.07 on August 17, erasing gains from three consecutive advancing sessions, as investors digested a...
🔴 BioXcel Therapeutics is trading 10.1% down in pre-market as Q2 revenue and EPS miss estimates
BioXcel Therapeutics is trading at $1.07, down -10.10% after its August 13, 2026 Q2 earnings release missed expectations. - EPS was -$0.490 versus -$0.423...
🔴 BioXcel Therapeutics trading 5% down in pre-market after Q2 earnings miss
BioXcel Therapeutics is trading 5% down in pre-market at $1.13 after reporting a Q2 earnings miss and revenue falling short of estimates. The company...
BioXcel Amends Credit Agreement, Extends Transaction Deadline and Lowers Liquidity Covenant
BioXcel Therapeutics has entered into a twelfth amendment to its credit agreement with lenders, providing a deadline extension to secure a strategic...
BioXcel Therapeutics secures 12th debt amendment, slashing minimum cash to $3M
BioXcel Therapeutics amended its credit agreement with Oaktree Fund Administration to gain temporary financial relief. The agreement lowers the company's...